311 related articles for article (PubMed ID: 22777336)
21. Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.
Bruyere O; Varela AR; Adami S; Detilleux J; Rabenda V; Hiligsmann M; Reginster JY
Eur J Epidemiol; 2009; 24(11):707-12. PubMed ID: 19728118
[TBL] [Abstract][Full Text] [Related]
22. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitors do not induce change in bone mineral density in a long-term observational study.
Madanick RD
Evid Based Med; 2013 Oct; 18(5):192-3. PubMed ID: 23220469
[No Abstract] [Full Text] [Related]
24. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Fournier MR; Targownik LE; Leslie WD
Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
[TBL] [Abstract][Full Text] [Related]
25. Women's Mid-Life Night Sweats and 2-Year Bone Mineral Density Changes: A Prospective, Observational Population-Based Investigation from the Canadian Multicentre Osteoporosis Study (CaMos).
Wong EMM; Tomlinson G; Pinto MM; Berger C; Cheung AM; Prior JC
Int J Environ Res Public Health; 2018 May; 15(6):. PubMed ID: 29861446
[TBL] [Abstract][Full Text] [Related]
26. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
27. Preoperative bone health assessment and optimization in spine surgery.
Anderson PA; Kadri A; Hare KJ; Binkley N
Neurosurg Focus; 2020 Aug; 49(2):E2. PubMed ID: 32738805
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure.
Targownik LE; Goertzen AL; Luo Y; Leslie WD
Am J Gastroenterol; 2017 Jan; 112(1):95-101. PubMed ID: 27845341
[TBL] [Abstract][Full Text] [Related]
29. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos).
Tenenhouse A; Joseph L; Kreiger N; Poliquin S; Murray TM; Blondeau L; Berger C; Hanley DA; Prior JC;
Osteoporos Int; 2000; 11(10):897-904. PubMed ID: 11199195
[TBL] [Abstract][Full Text] [Related]
30. Differences in fracture prevalence and in bone mineral density between Chinese and White Canadians: the Canadian Multicentre Osteoporosis Study (CaMos).
Morin SN; Berger C; Liu W; Prior JC; Cheung AM; Hanley DA; Boyd SK; Wong AKO; Papaioannou A; Rahme E; Goltzman D;
Arch Osteoporos; 2020 Sep; 15(1):147. PubMed ID: 32955674
[TBL] [Abstract][Full Text] [Related]
31. A Frailty Index predicts 10-year fracture risk in adults age 25 years and older: results from the Canadian Multicentre Osteoporosis Study (CaMos).
Kennedy CC; Ioannidis G; Rockwood K; Thabane L; Adachi JD; Kirkland S; Pickard LE; Papaioannou A
Osteoporos Int; 2014 Dec; 25(12):2825-32. PubMed ID: 25103215
[TBL] [Abstract][Full Text] [Related]
32. Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study.
Palmowski A; Schmajuk G; Yazdany J; Katz P; Li J; Stovall R; Kersey E; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Schneider U; Alexander T; Muche B; Hermann S; Wiebe E; Buttgereit F
Mayo Clin Proc; 2024 Jul; 99(7):1046-1057. PubMed ID: 38752948
[TBL] [Abstract][Full Text] [Related]
33. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
34. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
35. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Takakuwa M; Iwamoto J; Itabashi K
Clin Drug Investig; 2012 Feb; 32(2):121-9. PubMed ID: 22185631
[TBL] [Abstract][Full Text] [Related]
36. Physical activity, body mass index and bone mineral density-associations in a prospective population-based cohort of women and men: the Canadian Multicentre Osteoporosis Study (CaMos).
Langsetmo L; Hitchcock CL; Kingwell EJ; Davison KS; Berger C; Forsmo S; Zhou W; Kreiger N; Prior JC;
Bone; 2012 Jan; 50(1):401-8. PubMed ID: 22154839
[TBL] [Abstract][Full Text] [Related]
37. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.
Bruyère O; Roux C; Badurski J; Isaia G; de Vernejoul MC; Cannata J; Ortolani S; Slosman D; Detilleux J; Reginster JY
Curr Med Res Opin; 2007 Dec; 23(12):3041-5. PubMed ID: 17967221
[TBL] [Abstract][Full Text] [Related]
38. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
39. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.
Fraser LA; Langsetmo L; Berger C; Ioannidis G; Goltzman D; Adachi JD; Papaioannou A; Josse R; Kovacs CS; Olszynski WP; Towheed T; Hanley DA; Kaiser SM; Prior J; Jamal S; Kreiger N; Brown JP; Johansson H; Oden A; McCloskey E; Kanis JA; Leslie WD;
Osteoporos Int; 2011 Mar; 22(3):829-37. PubMed ID: 21161508
[TBL] [Abstract][Full Text] [Related]
40. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial.
Cheung AM; Tile L; Cardew S; Pruthi S; Robbins J; Tomlinson G; Kapral MK; Khosla S; Majumdar S; Erlandson M; Scher J; Hu H; Demaras A; Lickley L; Bordeleau L; Elser C; Ingle J; Richardson H; Goss PE
Lancet Oncol; 2012 Mar; 13(3):275-84. PubMed ID: 22318095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
